Prescient Therapeutics Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PSTTF research report →
Price Chart
About the company
Operating from Melbourne, Australia, Prescient Therapeutics Limited is a clinical-stage oncology company dedicated to pioneering novel pharmaceutical treatments for a variety of cancers. The company's primary investigational therapy, PTX-200, is currently undergoing several advanced clinical trials: a Phase 2a study for HER2-negative breast cancer, a Phase 1B/2 trial addressing relapsed and refractory acute myeloid leukemia (AML), and a Phase 1b trial for platinum-resistant ovarian cancer that has recurred or persisted. Another key pipeline asset is PTX-100, a RhoA inhibitor, engineered to combat both blood and solid tumors, particularly those characterized by specific Ras and RhoA genetic mutations.
- CEO
- Steven Lee Yatomi-Clarke
- IPO
- 2017
- HQ
- Melbourne, VIC, AU
Get TickerSpark's AI analysis on PSTTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $117.53M
- P/E
- -7.62
- PEG
- 0.51
- P/S
- 26.05
- P/B
- 4.55
- EV/EBITDA
- -7.12
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -323.82%
- Net Margin
- -285.08%
- ROE
- -62.49%
- ROIC
- -33.53%
- 52W High
- $0.14
- 52W Low
- $0.02
- 50D MA
- $0.06
- 200D MA
- $0.05
- Beta
- 1.04
- RSI (14)
- 41
- Avg Volume
- 0
No earnings-call transcripts are available for PSTTF yet.
- Free Float
- 84.9%
- Shares Outstanding
- 810.53M
- Float Shares
- 688.47M
Our PSTTF coverage
Recent articles, reports, and earnings notes.
No research on PSTTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PSTTF report →Dow Jones, S&P 500 gain on rate cut hopes as shutdown cancels key inflation, jobs reports
proactiveinvestors.com · Nov 21
Prescient secures EMA Orphan Drug Designation for PTX-100 in CTCL
proactiveinvestors.com · Nov 19
'Church-tech' firm Gloo Holdings makes $600m stock market debut
proactiveinvestors.com · Nov 19
Prescient Therapeutics prepares for transformative year with new CEO and key FDA clearance
https://www.proactiveinvestors.com · Jan 31
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.